How cancer play Pi plans to deploy $19.7M series B

Existing investor Pontifax led a $19.7 million series B round for Pi, which is developing protein degradation modulators for drug-resistant multiple myeloma and solid tumor indications based on technology licensed from Johns Hopkins University.

Founded in 2015, Pi Therapeutics (Ness Ziona, Israel) believes its next-generation ubiquitin proteasome inhibitors can overcome limitations of resistance and toxicity that have emerged with first-generation proteasome inhibitors such as Velcade bortezomib...